MAIA Biotechnology Inc (MAIA)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.14+5.56%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MAIA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
MAIA — M&A activity — Termination
Dated 2026-05-14
Termination of a Material Definitive Agreement. On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination wi…
Why it matters: MAIA said it plans to open four more U.S. sites in 2026. More sites would show progress in expanding the trial.
Supportive ifMAIA confirms four additional U.S. sites opened in 2026 for the THIO-101 expansion trial.
Worry ifMAIA reports fewer than four additional U.S. sites opened by the end of 2026, or delays the plan.
Why it matters: MAIA said the raise should fund its Phase 3 trial through completion. That matters as cash use rises.
Watch forMAIA reports enough cash to complete THIO-104 without another share sale.
Also watch forMAIA reports that THIO-104 needs more funding before completion or announces another share sale for the trial.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$175 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $764 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,373 loss on $10,000 · 63.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.